Keith Kidd
Family · Charleston, TNNPI 1811168941
Payments from drug & device makers
Across 272 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Bayer$480
- Axsome Therapeutics, Inc.$385
- Lilly USA, LLC$275
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$267
- plus $1K from 25 others
What the payments were for
- Food & beverage$5,14999%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $1,281 |
| AbbVie | 67 | $1,151 |
| Bayer | 32 | $480 |
| Axsome Therapeutics, Inc. | 14 | $385 |
| Lilly USA, LLC | 21 | $275 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $267 |
| Otsuka America Pharmaceutical, Inc. | 13 | $240 |
| Vanda Pharmaceuticals Inc. | 3 | $174 |
| Pfizer | 10 | $148 |
| Amgen | 6 | $104 |
| Almatica Pharma LLC | 5 | $90 |
| Novo Nordisk | 4 | $67 |
| Scilex Pharmaceuticals Inc. | 4 | $57 |
| Lundbeck LLC | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $46 |
| GSK | 3 | $40 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $29 |
| Boston Scientific | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| Medtronic | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,222 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $96,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $71,420 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $57,271 |
| FarxigaDapagliflozin Propanediol | 53 | $50,061 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $35,783 |
| EliquisApixaban | 49 | $33,378 |
| RybelsusSemaglutide | 22 | $31,551 |
| VascepaIcosapent Ethyl | 47 | $30,065 |
| VraylarCariprazine Hcl | 17 | $26,332 |
| JanuviaSitagliptin Phosphate | 44 | $24,829 |
| RexultiBrexpiprazole | 15 | $22,845 |
| Xigduo XrDapaglifloz Propaned/Metformin | 26 | $21,339 |
| JardianceEmpagliflozin | 18 | $21,191 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $20,639 |
| TrulicityDulaglutide | 21 | $19,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $67 | $137,120126 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,281 | $85,84399 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $40 | $77,403124 claims |
| AbbVieVraylar, Linzess | $1,151 | $41,80831 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $275 | $33,91535 claims |
| PfizerEliquis | $148 | $33,37849 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $240 | $22,84515 claims |
| Boehringer IngelheimJardiance | $31 | $21,19118 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $40 | $20,63924 claims |
| BayerKerendia | $480 | $14,46321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $5,74312 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $57 | $2,27116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Charleston
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.